Cancer Formation

A new treatment may soon bring relief to people suffering from pulmonary sarcoidosis, a serious lung disease with few good treatment options. The discovery comes from research led by Dr. Paul Schimmel of Scripps Research, a longtime scientist supported by the National Foundation for Cancer Research (NFCR). The team’s findings were recently published in Science Translational Medicine. What is Pulmonary Sarcoidosis? Sarcoidosis is a type of interstitial lung disease (ILD) where the immune system goes into overdrive, forming clusters of inflammatory cells—called granulomas—in the lungs. These can cause scarring and breathing problems. Current treatments mainly rely on steroids, which can have serious side effects like weight gain, bone loss, and a higher risk of infections. Is sarcoidosis cancer? It is not considered cancer but sometimes is mistaken as such.   What Did Paul Schimmel & Team Discover? Dr. Schimmel’s team created a new therapy called efzofitimod, based on a natural protein found in lung tissue. This engineered version is designed to calm the immune system in a more targeted way. Instead of shutting down the whole immune system like steroids do, efzofitimod focuses on specific immune cells that cause inflammation. Efzofitimod works by attaching to a receptor called neuropilin-2 (NRP2), found on certain immune cells that become overactive in lung disease. This helps reduce inflammation and lung damage while keeping the rest of the immune system working normally. In lab and animal studies, efzofitimod reduced inflammation and scarring in several types of ILD. In a small clinical trial, patients with sarcoidosis were able to lower their steroid doses while keeping their lung function stable and reducing inflammatory markers. “This isn’t a drug that shuts down the immune system,” said Dr. Leslie Nangle, co-lead author of the study. “It guides the immune response in a gentler, more natural way.” While the study focused on sarcoidosis, scientists believe efzofitimod could also help people with other inflammatory lung diseases. It may even lead to a new class of more targeted immune therapies. This research was partly supported by NFCR, showing how cancer research can lead to breakthroughs in other diseases, too. Make a Gift Today to Support Breakthroughs in Cancer Research>>> About Paul Schimmel Dr. Paul Schimmel, a distinguished biophysical chemist, has been collaborating with the National Foundation for Cancer Research (NFCR) since 1994. His research focuses on aminoacyl-tRNA synthetases (aaRS), enzymes crucial for gene expression. Supported by NFCR funding, Dr. Schimmel and his collaborator, Dr. Xiang-Lei Yang, have uncovered that certain aaRS enzymes are linked to diseases such as chronic and acute inflammation, neuropathy, and cancer progression. Notably, their work on SerRS has demonstrated its potential as an anti-tumor and anti-metastasis agent, offering promising avenues for cancer therapy. Sign-up to Stay Informed About Cancer Research Breakthroughs with NFCR!

From Curiosity to Cure The latest episode of All Things Cancer features a powerful conversation with Nobel Laureate Dr. James Allison, whose work in immunotherapy has transformed cancer treatment across the globe. Hosted by Dr. Sujuan Ba, the episode dives into Dr. Allison’s early curiosity about the immune system, the years of resistance he faced from the scientific community, and the unforgettable moment when a patient’s tumors disappeared after receiving the drug he helped develop. More than a story of scientific discovery, it reminds us of the persistence, creativity, and support needed to turn bold ideas into life-saving treatments. Listen Now on Spotify | Apple Podcasts | and YouTube. About All Things Cancer Each episode of All Things Cancer will spotlight the most pressing topics in oncology, from cutting-edge treatments and emerging research to personal stories of resilience and hope. More than just a podcast, it’s a platform for raising awareness, advancing cancer education, and fostering a global community of support and collaboration. Hosted by NFCR CEO Sujuan Ba, Ph.D., this compelling series will bring together the entire ecosystem of cancer research—including leading scientists, oncologists, doctors, patient advocates, caregivers, biotech innovators, and survivors—for powerful discussions on the breakthroughs shaping the future of cancer research, treatment, and care. All Things Cancer is now available on Spotify and Apple Podcasts, with new episodes released biweekly. Stay up to date on the latest episodes and join the conversation that’s shaping the future of cancer research. Cancer impacts everyone—whether you're a patient, caregiver, advocate, or researcher, this podcast delivers invaluable insights from those on the frontlines of the fight against it. Sign-up to Be Informed When the Next Episode Comes Out!

Something special happens when a community comes together with a shared purpose, and this year’s Daffodils & Diamonds Luncheon was no exception. Held on March 6th at the Columbia Country Club in Chevy Chase, the 42nd Annual Daffodils & Diamonds brought supporters, survivors, and advocates together for an afternoon filled with warmth, generosity, and hope, all in support of advancing cancer research through the National Foundation for Cancer Research (NFCR). Generations of Tradition, A New Chapter of Impact What began decades ago as a tribute to loved ones lost to cancer has grown into a powerful and enduring tradition. Over the years, this event has become not just a fundraiser but a celebration of life, progress, and the unshakable belief that we can—and will—find a cure.   This year, that spirit was stronger than ever. Guests participated in a lively silent auction, exciting raffles, and a stunning fashion show, all while supporting a cause that touches so many lives. And thanks to their incredible generosity, more than $110,000 was raised—funds that will directly support NFCR’s efforts to make cures possible with high-impact cancer research. A Conversation—and a Speech—that Inspired One of the day’s most impactful moments came from Dr. Azra Raza, renowned oncologist and author of The First Cell. She first joined event emcee and long-time news anchor Alison Starling for an insightful on-stage conversation, where she shared her expert perspective on the future of cancer research and the need for bold innovation. Her enthusiasm was contagious, and captivated the audience. Later in the program, Dr. Raza delivered a powerful speech that resonated deeply with attendees. One line in particular stood out: “Where cancer is concerned, we need to unblind ourselves.” Her words served as a poignant reminder of the urgency to shift how we approach cancer detection and treatment—and the critical importance of continued support for research. Honoring Resilience and Renewing Purpose A highlight of the afternoon was the celebration of cancer survivors, whose strength and stories served as both a reminder of the progress made and a call to keep pushing forward. Their presence brought the mission of Daffodils & Diamonds to life in the most meaningful way. Keep the Momentum Going It’s hard to say just how impactful a day like this can be. However, one thing is certain: when a community comes together with compassion and commitment, change happens. Whether you joined us in person or supported us from afar, thank you for being part of this incredible day. Together, we’re making cures possible. Want to keep making a difference? There are so many ways to get involved—donate, volunteer, or even host your own event to support NFCR’s lifesaving cancer research programs. Reach out to us at community@nfcr.org to learn more. Sign-up to Stay Informed About Cancer Research Breakthroughs with NFCR!